These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29604495)

  • 1. Is alpha-fetoprotein decline a prognostic factor of childhood non-seminomatous germ cell tumours? Results of the French TGM95 study.
    Fresneau B; Orbach D; Faure-Conter C; Sudour-Bonnange H; Vérité C; Gandemer V; Pasquet M; Fasola S; Rome A; Raimbault S; Martelli H; Frappaz D; Le Teuff G; Patte C
    Eur J Cancer; 2018 May; 95():11-19. PubMed ID: 29604495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Childhood ovarian nonseminomatous germ cell tumors: A highly curable disease with few long-term treatment-related toxicities-Results of the French TGM95 study.
    Pavone R; Pacquement H; Pasquet M; Sudour-Bonnange H; Hameury F; Sarnacki S; Chastagner P; Faure-Conter C; Poirée M; Taque S; Patte C; Fresneau B
    Int J Cancer; 2021 Nov; 149(9):1705-1712. PubMed ID: 34146403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracranial germ cell tumours in children and adolescents: Results from the French TGM13 protocol.
    Faure-Conter C; Orbach D; Sudour-Bonnange H; Verité C; Mansuy L; Rome A; Dumesnil C; Thebaud E; Renard M; Hameury F; Flechon A; Blanc E; Dijoud F; Fresneau B; Chabaud S
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30117. PubMed ID: 36451268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
    Raggi D; Mariani L; Giannatempo P; Lo Vullo S; Giardiello D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Calareso G; Magni M; Di Nicola M; Verzoni E; Grassi P; Procopio G; De Braud F; Pizzocaro G; Salvioni R; Necchi A
    Urol Oncol; 2015 Jul; 33(7):332.e19-24. PubMed ID: 25985712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of tumor size, metastases, extension into bone, and increased tumor marker in children with malignant sacrococcygeal germ cell tumors: a prospective evaluation of 71 patients treated in the German cooperative protocols Maligne Keimzelltumoren (MAKEI) 83/86 and MAKEI 89.
    Calaminus G; Schneider DT; Bökkerink JP; Gadner H; Harms D; Willers R; Göbel U
    J Clin Oncol; 2003 Mar; 21(5):781-6. PubMed ID: 12610174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
    You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
    Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of preoperative alpha-fetoprotein as an ovarian tumor marker in children and adolescents: not as good as we thought?
    Loh AH; Gee KW; Chua JH
    Pediatr Surg Int; 2013 Jul; 29(7):709-13. PubMed ID: 23653236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The prognostic significance of serum alpha 1-fetoprotein in children and adolescents with malignant extracranial non-testicular germ cell tumors].
    Calaminus G; Vesterling-Hörner D; Bökkerink JP; Gadner H; Günther G; Haas HJ; Jürgens H; Teske C; Göbel U
    Klin Padiatr; 1991; 203(4):246-50. PubMed ID: 1719268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in children with localized malignant nonseminomatous germ cell tumors.
    Baranzelli MC; Kramar A; Bouffet E; Quintana E; Rubie H; Edan C; Patte C
    J Clin Oncol; 1999 Apr; 17(4):1212. PubMed ID: 10561181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actual half-life of alpha-fetoprotein as a prognostic tool in pediatric malignant tumors.
    Han SJ; Yoo S; Choi SH; Hwang EH
    Pediatr Surg Int; 1997; 12(8):599-602. PubMed ID: 9354734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
    Gerl A; Clemm C; Lamerz R; Mann K; Wilmanns W
    Eur J Cancer; 1993; 29A(7):961-5. PubMed ID: 7684597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
    Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
    Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium.
    O'Neill AF; Xia C; Krailo MD; Shaikh F; Pashankar FD; Billmire DF; Olson TA; Amatruda JF; Villaluna D; Huang L; Malogolowkin M; Rodriguez-Galindo C; Frazier AL
    Cancer; 2019 Oct; 125(20):3649-3656. PubMed ID: 31355926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lectin-reactive alpha-fetoprotein (AFP-L3%) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors.
    Kamoto T; Satomura S; Yoshiki T; Okada Y; Henmi F; Nishiyama H; Kobayashi T; Terai A; Habuchi T; Ogawa O
    Jpn J Clin Oncol; 2002 Nov; 32(11):472-6. PubMed ID: 12499420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors.
    Mego M; Rejlekova K; Reckova M; Sycova-Mila Z; Obertova J; Rajec J; Mardiak J
    Neoplasma; 2009; 56(5):398-403. PubMed ID: 19580341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
    Massard C; Kramar A; Beyer J; Hartmann JT; Lorch A; Pico JL; Rosti G; Droz JP; Fizazi K
    Ann Oncol; 2013 Feb; 24(2):322-328. PubMed ID: 23104726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant extra-cranial germ cell tumors in children and adolescents. Results following the guidelines of SFOP/SFCE 95 Protocol.
    Zubizarreta P; Rossa A; Bailez M; Gil S; Rose A; Cacciavillano W
    Medicina (B Aires); 2016; 76(5):265-272. PubMed ID: 27723613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.
    de la Motte Rouge T; Pautier P; Genestie C; Rey A; Gouy S; Leary A; Haie-Meder C; Kerbrat P; Culine S; Fizazi K; Lhommé C
    Gynecol Oncol; 2016 Sep; 142(3):452-7. PubMed ID: 27401840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of germ cell tumors in children: approaches to cure.
    Göbel U; Calaminus G; Schneider DT; Schmidt P; Haas RJ;
    Onkologie; 2002 Feb; 25(1):14-22. PubMed ID: 11893878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
    Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
    Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.